CG Oncology, Inc. Common stock
NASDAQ:CGONBiotechnology
+$1.35 today
- Market cap
- $7.15B
- Beta
- 0.31
- P/E (TTM)
- -28.0
- EPS (TTM)
- -$2.21
Volume 1.79M
Average 1.08M
CGON Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
CG Oncology, Inc. Common stockNASDAQ: CGON
Change in Working Capital · Q3 FY2026 · quarter ended Sep 2026
Change in working capital growth accelerates
Q3 FY2026 change in working capital of $5.82M (cash outflow) rose 102.5% year over year, ahead of the -110.7% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -20.0% a year.
Context
- Change in working capital amounted to 56.3% of revenue in FY2025, down 198.8 pp from a year earlier.
- Change in working capital increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +102.5% holds above the trailing-twelve-month pace of -110.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 2.28M USD
- Year-over-year change
- -21.7%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.28M | -21.7% |
| FY2024 | 2024-12-31 | 2.91M | -15.5% |
| FY2023 | 2023-12-31 | 3.44M | -22.5% |
| FY2022 | 2022-12-31 | 4.44M | +325.7% |
| FY2021 | 2021-12-31 | (1.97M) | — |
Change in Working Capital vs competitors
How CGON compares with its peers on the latest reported figures
- CGON's LTM Sep 2026 change in working capital of $1.2M is the smallest of the 3 companies compared; the peer median is $29.65M.
- Its year-over-year change of -110.7% is the 2nd highest of 3, against a peer median of -513.1%.
- Change in working capital amounts to 19.4% of revenue for CGON, versus a peer median of 20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $53.19M | -938.3% | +64.2% | 37.9% | |
| LTM Sep 2026 | $6.11M | -88.0% | +50.3% | 3.3% | |
| LTM Sep 2026 | $1.2M | -110.7% | -20.0% | 19.4% | |
| Peer median (excluding CGON) | $29.65M | -513.1% | +57.2% | 20.6% | |
Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.84M) | (35.44M) | (48.61M) | (88.04M) | (161M) |
| Depreciation & Amortization | 10K | 15K | 17K | 32K | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.11M | 676K | 1.53M | 11.4M | 26.68M |
| Change in Working Capital | (1.97M) | 4.44M | 3.44M | 2.91M | 2.28M |
| Accounts Receivables | 0 | 0 | 0 | (689K) | (320K) |
| Inventory | 0 | 0 | 0 | 0 | (444K) |
| Accounts Payables | 578K | (18K) | 2.01M | 3.28M | (1.64M) |
| Other Working Capital | (2.55M) | 4.46M | 1.43M | 320K | 4.68M |
| Other Non-Cash Items | 30K | 509K | (2.06M) | (5.01M) | (1.75M) |
| Operating Cash Flow | (13.65M) | (29.8M) | (45.68M) | (78.71M) | (132.35M) |
| Capital Expenditures | (97K) | (14K) | 0 | (234K) | (134K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (21.97M) |
| Purchases of Investments | 0 | (55.34M) | (517.61M) | (1.05B) | (1.07B) |
| Sales of Investments | 0 | 0 | 396.42M | 745.41M | 844.14M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (97K) | (55.35M) | (121.2M) | (300.76M) | (245.82M) |
| Debt Repayment | 15.2M | 0 | (16.29M) | (365K) | 0 |
| Common Stock Issued | 245K | 166K | 2.08M | 629.47M | 153.59M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (3.42M) | (825K) | 0 |
| Financing Cash Flow | 15.45M | 119.69M | 87M | 628.28M | 153.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.7M | 34.54M | (79.88M) | 248.8M | (224.58M) |
| Free Cash Flow | (13.75M) | (29.82M) | (45.68M) | (78.95M) | (132.48M) |
CG Oncology, Inc. Common stock
NASDAQ:CGON
Intrinsic Alpha fair value
Locked
Current Price
$80.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.